Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 11 of the 90 sources its claims cite were checked for support.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.
Overview
CoChat Summary
TL;DR
This review discusses controversies in the pathogenesis, diagnosis, and treatment of polycystic ovary syndrome (PCOS), focusing on insulin resistance, inflammation, and hyperandrogenism. It argues that therapy must be individualized and that, apart from combined oral contraceptives (COCs), most drugs used for PCOS remain off-label, with larger and longer-term studies needed.
Key findings
- PCOS prevalence varies by diagnostic criteria: 4–8% by NIH/NICHD criteria and approximately 18% by Rotterdam criteria; the Rotterdam criteria are endorsed by a recent international evidence-based guideline.
- Insulin resistance is common in PCOS, worsened by hyperandrogenism-related adipose tissue accumulation, and compensatory hyperinsulinemia stimulates ovarian theca androgen production and decreases hepatic SHBG synthesis, increasing total and free androgens.
- Chronic low-grade inflammation is associated with increased white blood cell count, CRP, IL-6, IL-18, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1; aldosterone and the aldosterone/renin ratio are often increased in PCOS and may accentuate inflammation and metabolic/cardiovascular disorders.
- Treatment should start with lifestyle improvement; metformin, inositols (with a MYO:DCI ratio of 40:1 described as most effective), GLP-1 receptor agonists, and SGLT2 inhibitors are discussed, while COCs and antiandrogens have benefits and risks; spironolactone is preferred among antiandrogens because it also has anti-inflammatory action.
Methods
- Narrative review of published literature on PCOS pathogenesis, diagnosis, and treatment, with emphasis on insulin resistance, inflammation, and hyperandrogenism.
- The paper synthesizes prior studies and guidelines, including diagnostic criteria, PCOS phenotypes A–D, androgen measurement issues, insulin resistance assessment, and therapeutic options.
- No primary data collection, new patient sample, or systematic meta-analysis is described.
Limitations
- Stated: many PCOS drugs are off-label; more randomized controlled trials and long-term studies are needed; larger samples are needed to evaluate new therapies and inflammation in adipose tissue; microbiome role requires further study; studies of third-generation contraceptives are short-term, discordant, and often limited in patient numbers.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or new empirical data, so conclusions rely on interpretation of cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 7 Not valid · 66 Not checked · 16 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The administration of drugs with anti-androgenic activity improves insulin resistance [26].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 4. The Pathogenetic Role of Hyperandrogenism in PCOS
What the sources say
- Disputedcites [26] Armanini, 2016, Spironolactone in the treatment of polycystic ovary syndrome, Expert Opin. Pharmacother. sourceExperimental — accuracy not yet measured
Section 3 (page unavailable) discusses hormonal contraceptives containing progestins with antiandrogenic activity, but says the available data do not demonstrate a positive or negative effect on insulin resistance. The paper discusses spironolactone’s benefits for androgen-related symptoms; it does not establish the claimed improvement in insulin resistance. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“insulin resistance, a very common condition in PCOS, which is worsened by hyperandrogenism-related adipose tissue accumulation [3] and is involved in both the pathogenesis and the progression of the disease [4].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 1. Introduction
What the sources say
- Supportedcites [3] Dumesic, 2020, Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective, Curr. Opin. Endocr. Metab. Res. source
The Insulin resistance section states that 60–95% of women with PCOS have insulin resistance, supporting the description of it as very common. (LLM, conf=0.95)
- Not checked yetcites [4] Dunaif, 2012, Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications, Endocr. Rev. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another important pro-inflammatory agent involved in the pathogenesis of PCOS is adipose tissue [18].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 3. The Pathogenetic Role of Inflammation in PCOS
What the sources say
- Partly supportedcites [18] Makki, 2013, Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines, ISRN Inflamm. sourceExperimental — accuracy not yet measured
Our copy supports the general half of the claim: Section 1 states that obesity is a proinflammatory condition and that 'white adipose tissue (WAT) is the key site mediating systemic inflammation,' and Section 1.1 that obese adipose tissue mainly releases proinflammatory cytokines (TNF-α, IL-6, leptin, resistin...) contributing to insulin resistance. PCOS appears only once, in Section 1, where 'polycystic ovarian diseases' is listed among metabolic diseases for which excess adiposity is an established risk factor (citing ref [1]) — a risk-factor statement, not a pathogenic mechanism. The source nowhere attributes to adipose tissue a pro-inflammatory role in the pathogenesis of PCOS specifically; its scope is obesity-induced inflammation and insulin resistance/T2D (Section 3, Concluding Remarks). The PCOS-specific causal/pathogenic part of the citing sentence is unsupported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ideally, a progestin with the lowest possible androgenic action such as cyproterone acetate, chlormalidone, and drospirenone should be used. However, they have been associated with increased risk of venous thrombosis [65,66,67].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.2. Hormonal Contraceptives
What the sources say
- Not checked yetcites [65] Bird, 2013, Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of ethinyl-estradiol?, J. Thromb. Haemost. source
- Partly supportedcites [66] Cushman, 2004, Estrogen plus progestin and risk of venous thrombosis, JAMA sourceExperimental — accuracy not yet measured
The COMMENT section reports increased venous-thrombosis risk with estrogen plus progestin in postmenopausal women. But the Participants section identifies the studied progestin as medroxyprogesterone acetate; the paper does not establish the claimed association for cyproterone acetate, chlormalidone, or drospirenone, or address their androgenic action. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [67] Gronich, 2011, Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study, CMAJ sourceExperimental — accuracy not yet measured
The Results report increased venous-thrombosis risk with drospirenone-containing contraceptives relative to second- and third-generation contraceptives. They do not establish the same association for cyproterone acetate or chlormadinone; the Results explicitly say the chlormadinone sample was too small to analyze. The source therefore supports the risk claim for drospirenone, but not for all three named progestins. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, the most studied medication is metformin, which seems to positively influence microbiota diversity and composition [61].”
§ Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism > 6. Controversies in the Treatment of PCOS > 6.1. Insulin Sensitizers
What the sources say
- Partly supportedcites [61] Montandon, S.A., and Jornayvaz, F.R. (2017). Effects of antidiabetic drugs on gut microbiota composition. Genes, 8. sourceExperimental — accuracy not yet measured
Section 3 (Discussion) describes metformin as the most studied medication and reports increases in potentially beneficial bacteria, supporting the composition part. But Section 2.2 (Biguanides) says its effects on diversity are diet-dependent and reports decreased bacterial diversity in mice on a high-fat diet. The paper therefore does not support an unqualified positive effect on diversity. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 1 with their cited sources checked
Create a free account to see all 98 claims and to verify the 79 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, chronic low-grade inflammation is commonly observed in this population, contributing to metabolic dysregulation and an increased risk of comorbidities such as T2DM and cardiovascular disease13.”
From Cross-sectional study of the relationship between dietary inflammatory index and inflammatory hormonal and metabolic profiles in polycystic ovary syndrome (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, myoinositol might improve oocyte and embryo quality [5] by encouraging translocation of GLUT4 to the plasma membrane in order to increase glucose uptake [53] and promote aromatase activity.”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperinsulinaemia, however, can contribute to certain obesity complications or related diseases, including hormonal disorders related to sex hormones and cancer (ie, mitogenic effect of insulin).98,99”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In women, hormonal dysfunction of adipose tissue and hyperinsulinaemia (which can act as a gonadotrophin) from insulin resistance constitute the main links to development of functional hyperandrogenism or polycystic ovary syndrome.98”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“As direct assays to measure free testosterone are not entirely reliable, another useful tool for the assessment of biochemical hyperandrogenism is free testosterone calculated using the formula of Vermeulen and collogues [36].”
MethodThe Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 3×
“In skeletal muscle, the inhib ion of phosphoi sitide-3 kinase nd phosp orylation of i sulin recep or sub trate 1 le ds to impaired insulin signali g by altering the GLUT-4 xpression and glucose uptake [6,7].”
BackgroundInsulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The second problem is related to the various methods of measurement (fasting insulin or after glucose loading), which do not correlate with what has been found using more accurate and sophisticated laboratory methods [40].”
MethodBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456 · cited 1×
“In clinical practice, HOMA-IR is the most common test used in research studies to measure insulin resistance, as it has been shown to closely approximate the results of clamp studies over many years [41,42].”
ResultAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“However, this latter phenotype is not included among PCOS according to the Androgen Excess Society guideline, which suggests the presence of both hyperandrogenism and ovarian dysfunction [31].”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“In particular, insulin and LH act synergistically on the theca cells, stimulating ovarian androgen production [4].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Cited by
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
“98 The clinical symptoms of these disorders are menstruation disturbances (due to impaired ovulation), hirsutism, acne, and impaired fertility.”
InfluentialZhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
“Studies suggest that a more complex evaluation of the decrease in insulin sensitivity as a continuous variable is required in clinical practice [10].”
BackgroundGreff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“In addition, myoinositol might improve oocyte and embryo quality [5] by encouraging translocation of GLUT4 to the plasma membrane in order to increase glucose uptake [53] and promote aromatase activity.”
BackgroundXiang, Y., Wang, H., Ding, H., Xu, T., Liu, X., Huang, Z., Wu, H., & Ge, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111141 · Cited by 142
Zhang, C.-H., Liu, X., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216247 · Cited by 146
Handelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 118
Lonardo, M. S., Cacciapuoti, N., Guida, B., Lorenzo, M. D., Chiurazzi, M., Damiano, S., & Menale, C. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00531-2 · Cited by 134
“Thus, IR, hyperandrogenism, hyperleptinemia, LGCI and adipose tissue hypertrophy and dysfunction may cooperate in the vicious cycle that contributes to the etiopathogenesis of PCOS [50].”
BackgroundPCOS Physiopathology and Vitamin D Deficiency: Biological Insights and Perspectives for Treatment
Morgante, G., Darino, I., Spanò, A., Luisi, S., Luddi, A., Piomboni, P., Governini, L., & De Leo, V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154509 · Cited by 95
“To date, the use of metformin in PCOS patients represents a milestone in therapy for these patients [9,10].”
BackgroundSignaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
Wang, K., & Lǐ, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1191759 · Cited by 127
Advances in the study of the correlation between insulin resistance and infertility
Lei, R., Chen, S., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1288326 · Cited by 96
Jabeen, A., Yamini, V., Amberina, A. R., Eshwar, M. D., Vadakedath, S., Begum, G. S., & Kandi, V. (2022) · Cureus · doi:10.7759/cureus.27943 · Cited by 128
“Moreover, untreated patients develop complications such as infertility, pregnancy-related issues, metabolic disorders, and cardiovascular diseases [9,10].”
BackgroundAustregésilo de Athayde De Hollanda Morais, B., Martins Prizão, V., de Moura de Souza, M., Ximenes Mendes, B., Rodrigues Defante, M. L., Cosendey Martins, O., & Rodrigues, A. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108834 · Cited by 68
Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis
Fahs, D., Salloum, D., Nasrallah, M., & Ghazeeri, G. S. (2023) · Diagnostics · doi:10.3390/diagnostics13091559 · Cited by 108
“Hyperandrogenism can result from an imbalance in the hypothalamus–pituitary–ovarian axis signaling process, leading to excess secretion of insulin and luteinizing hormone [18].”
BackgroundPCOS in Adolescents—Ongoing Riddles in Diagnosis and Treatment
Męczekalski, B., Niwczyk, O., Kostrzak, A., Maciejewska-Jeske, M., Bala, G., & Szeliga, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031221 · Cited by 92
“Although it is unclear whether hyperandrogenism is a cause or symptom of PCOS, an enzyme deficiency at any stage in the steroidogenic pathway is prognostic [10].”
BackgroundRoles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome
Koike, H., Harada, M., Kusamoto, A., Xu, Z., Tanaka, T., Sakaguchi, N., Kunitomi, C., Azhary, J. M. K., Takahashi, N., Urata, Y., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124405 · Cited by 58
Polycystic Ovarian Syndrome (PCOS): Does the Challenge End at Conception?
Mirza, F., Tahlak, M., Rjeili, R. B., Hazari, K., Ennab, F., Hodgman, C. T., Khamis, A. H., & Atiomo, W. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192214914 · Cited by 57
Parker, J. (2023) · Life · doi:10.3390/life13041056 · Cited by 45
Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Livadas, S., Thymis, J., Peppa, Μ., Kalantaridou, S., Oikonomou, E. K., et al. (2024) · Medicina · doi:10.3390/medicina60101656 · Cited by 63
Geng, L., Yang, X., Sun, J., Ran, X., Zhou, D., Ye, M., Li, W., Wang, R., & Chen, M. (2025) · Advanced Science · doi:10.1002/advs.202412558 · Cited by 49
Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance
Genazzani, A. D., & Genazzani, A. R. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.71 · Cited by 48
“When lipids are accumulated inside the hepatocytes, they activate the diacylglycerol/protein kinase C and inhibit the insulin receptor.(10) Inside the skeletal muscles, IR probably induces the inhibition of both the phosphoinositide3 kinase and the phosphorylation of insulin receptor substrate 1, thus changing the exp…”
BackgroundInfluentialBatóg, G., Dołoto, A., Bąk, E., Piątkowska‐Chmiel, I., Krawiec, P., Pac‐Kożuchowska, E., & Herbet, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1211231 · Cited by 50
Yang, Y., Zhou, C.-C., Hu, H., Fukuzawa, I., & Zhang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1035929 · Cited by 39
Rambaran, N., & Islam, M. S. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i7.108789 · Cited by 48
Yang, S., Liu, C., Ma, S., Chang, W.-H., Chen, Y., Lee, W.-L., & Wang, P. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159094 · Cited by 40
“9 kg/m2, and obese as BMI ≥ 30 kg/m2 [2,33], and most of studies adopted this classification [13,15–19,34–36].”
BackgroundEffects of intestinal flora on polycystic ovary syndrome
Liu, J., Liu, Y., & Li, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1151723 · Cited by 43
Hong, L., Xiao, S., Diao, L., Lian, R., Chen, C., Zeng, Y., & Liu, S. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05362-5 · Cited by 40
“…focused on elucidating the impact of hyperandrogenism on granulosa cell function, follicular development, ovarian dysfunction, and ovulation [61, 65–67], our study stands out by discovering an important correlation between androgen excess, glycolysis, and decidualization within the local…”
BackgroundA PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Unfer, V., Dinicola, S., & Russo, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076213 · Cited by 34
“Androgen excess correlates with alterations in the menstrual cycle and ovarian physiology and reduces the possibility of pregnancy [7].”
BackgroundBahreiny, S. S., Ahangarpour, A., Saki, N., Dabbagh, M. R., Ebrahimi, R., Mahdizade, A. H., Ghorbani, H., & Aghaei, M. (2024) · Reproductive Sciences · doi:10.1007/s43032-023-01447-x · Cited by 33
“PCOS is a disorder in women characterized by hormonal imbalance, ovarian cysts, irregularities in menstrual cycles, and metabolic disturbances [31].”
The role of the autonomic nervous system in polycystic ovary syndrome
Yu, Y., Chen, T., Zheng, Z., Jia, F., Liao, Y., Ren, Y., Liu, X., & Liu, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1295061 · Cited by 38
Hu, X., Chen, Y., Shen, Y., Zhou, S., Fei, W., Yang, Y., & Que, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1025267 · Cited by 36
“low-grade inflammation plays an important role in promoting the occurrence and development of PCOS (38, 39).”
BackgroundHe, Y., Li, R., Yin, J., Yang, Z., Wang, Y., Chen, L., Yang, S., & Qiao, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1204623 · Cited by 27
Chamanara, S., Hozouri, V., & Irandoost, E. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23592 · Cited by 28
Luo, M., Yang, X., Zhou, M., Zhang, J., Yu, B., Lian, H., & Ye, J. (2024) · iScience · doi:10.1016/j.isci.2024.111028 · Cited by 30
Yu, J., Zhou, Y., Ding, J., Zhang, D., Yu, C., & Huang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.970733 · Cited by 31
Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease
Alvarez, Y. R., Pico, M. G., Ashokprabhu, N. D., Abou-Amro, K., Bailey, S., Pung, E., Oberholster, E., & Quesada, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01168-1 · Cited by 27
“Additionally, insulin enhances luteinizing hormone activity and acts synergistically with luteinizing hormone on theca cells to stimulate ovarian androgen production [30].”
Zhang, Y., Chen, M., Li, Y., Guo, Y., Yu, Y., Zhi, Z., Hui, L., Si, Y., Wu, C., Zhang, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1457467 · Cited by 31
Circulating Galectin-3 levels in women with polycystic ovary syndrome: A meta-analysis
Bahreiny, S. S., Bastani, M., Aghaei, M., Dabbagh, M. R., & Mahdizade, A. H. (2024) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2023.10.003 · Cited by 30
Calcaterra, V., Cena, H., Sottotetti, F., Hruby, C., Madini, N., Zelaschi, N., & Zuccotti, G. (2023) · Nutrients · doi:10.3390/nu15163582 · Cited by 27
Xu, X., Xu, X., Wang, X., & Shen, L. (2023) · Pharmaceutical Biology · doi:10.1080/13880209.2023.2208636 · Cited by 25
“It is characterized by chronic anovulation (abnormal or lost ovulation) and hyperandrogenemia (Azziz 2018; Armanini et al. 2022).”
BackgroundPierro, F. D., Sultana, R., Eusaph, A. Z., Abrar, S., Bugti, M., Afridi, F., Farooq, U., Iqtadar, S., Ghauri, F., Makhduma, S., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1269605 · Cited by 34
Formononetin ameliorates polycystic ovary syndrome through suppressing NLRP3 inflammasome
Liu, Z., Wang, R., & Wang, K. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01092-x · Cited by 35
“Besides, TNF-α, IL-1β and IL-6 level was higher in the DHT + FMN (50 μmol/L) + Nigericin group than those in the DHT + FMN (50 μmol/L) group (Fig.”
InfluentialSikiru, A. B., Adeniran, M. A., Akinola, K., Behera, H., Kalaignazhal, G., & Egena, S. S. A. (2023) · Middle East Fertility Society Journal · doi:10.1186/s43043-023-00142-w · Cited by 30
Tharayil, S. P., & Shukla, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136233 · Cited by 33
“However, DCI supplementation could exacerbate insulin-mediated androgen production and fertility in women with PCOS [176,186].”
Luo, Z., Wang, L., Wang, Y., Fan, Y., Jiang, L., Xu, X. P., Du, Y., & Hao, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030818 · Cited by 28
“Excessive insulin also increased the proportion of free T, an active status for T to play a biological role, by suppressing the hepatic sex hormone-binding globulin (SHBG) synthesis and reducing circulated SHBG [37,38].”
BackgroundAlkheyr, Z., Murad, M. H., Das, P., Aljenaee, K., Kamel, C., Hajji, S. A., Flood, J., Atkin, S. L., & Ali, K. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301707 · Cited by 30
Cao, Z., Zhou, Q., An, J., Guo, X., Jia, X., & Qiu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s525651 · Cited by 34
“37 Altered expression of glucose transporters (GLUT) further restricts glucose availability, 38 while mitochondrial dysfunction leads to energy deficits and oxidative stress.”
Li, F., Qi, J.-J., Li, L., & Yan, T.-F. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.05.042 · Cited by 26
Butler, A. E., Nandakumar, M., Sathyapalan, T., Brennan, E., & Atkin, S. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010321 · Cited by 25
“PCOS includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance, and is associated with several metabolic diseases including diabetes [38].”
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 30
“Compensatory hyperinsulinemia induces overstimulation of non-insulin-sensitive tissues, including ovary (19).”
Parker, J., Briden, L., & Gersh, F. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124021 · Cited by 40
Babayev, E., Xu, M., Shea, L. D., Woodruff, T. K., & Duncan, F. E. (2022) · Molecular Human Reproduction · doi:10.1093/molehr/gaac033 · Cited by 24
Li, Z., Geng, H., Ye, C., Cao, L., Qin, R., Chen, K., Fu, Y., & Liu, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114038 · Cited by 26
Szkodziak, P. R., Szkodziak, F., Trzeciak, K., Woźniak, S., Mlynarczyk, M., & Paszkowski, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-26718-2 · Cited by 33
“Concurrent adipose inflammation, macrophage infiltration, fibrosis, and tissue expansion further exacerbate metabolic dysfunction 1,2,12–14 .”
Effects of ketogenic diets on polycystic ovary syndrome: a systematic review and meta-analysis
Cannarella, R., Rubulotta, M., Leonardi, A., Crafa, A., Calvo, A., Barbagallo, F., Vignera, S. L., & Calogero, A. E. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01411-1 · Cited by 23
“These factors also increase cardiovascular risk [29, 32].”
Xu, T., Xiang, Y., Huang, Z., Zhu, Q., Wu, H., Cai, J., Weng, L., & Ge, H. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01757-5 · Cited by 21
Parker, J., O'Brien, C. L., Yeoh, C., Gersh, F. L., & Brennecke, S. P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061774 · Cited by 23
“The aldosterone/renin ratio is often increased in women with PCOS and accentuates the inflammatory state [151,168].”
BackgroundInfluentialMirzohreh, S., Panahi, P., & Heidari, F. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02617-x · Cited by 20
“This metabolic dysfunction increases their susceptibility to developing cardiovascular risk factors, including insulin resistance [4], type 2 diabetes mellitus [5], coronary heart disease [6], atherogenic dyslipidemia [7], and cerebrovascular morbidity [8].”
BackgroundAjorlouie, Z., Moshkian, P., Baghdadi, G., Amiri, R., Biglari, F., & Rahimlou, M. (2025) · BMC Nutrition · doi:10.1186/s40795-025-01067-5 · Cited by 17
“PCOS as a chronic disease associated with insulin resistance as well as increased levels of inflammation and oxidative stress is correlated with various lifestyle and nutritional factors [29, 30].”
The role of β-hydroxybutyrate testing in ketogenic metabolic therapies
Fante, C., Spritzler, F., Calabrese, L. V., Laurent, N., Roberts, C. G. P., & Deloudi, S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1629921 · Cited by 20
“PCOS is a common and heterogeneous disorder, typically marked by hyperandrogenism, oligo-anovulation, and metabolic dysfunction, with a multifactorial pathogenesis often linked to insulin resistance, which contributes to ovarian dysfunction, inflammation, and metabolic complications (118).”
Zhao, H., Wang, D., Xing, C., Lv, B., Wang, X., & He, B. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106265 · Cited by 19
Elghobashy, M., Lau, G. M., Davitadze, M., Gillett, C. D. T., O’Reilly, M., Arlt, W., PCOS SEva Working Group, Lindenmeyer, A., & Kempegowda, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1175548 · Cited by 25
Mechanism and recent updates on insulin-related disorders
Kumar, S., Senapati, S., Bhattacharya, N., Bhattacharya, A., Maurya, S. K., Husain, H., Bhatti, J. S., & Pandey, A. K. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i25.5840 · Cited by 20
Jin, Y., Fei, S., Yang, A., Yu, X., Li, Y., Liang, S., Jing, X., Wang, K., Zhang, L., Xiao, S., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1279717 · Cited by 19
Zhu, M., Wang, K., Feng, J., Liu, Y., Guan, M., Wang, Y., & Wu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1502321 · Cited by 14
Effect and mechanism of resveratrol against polycystic ovary syndrome: a review
Chang, H., Shi, B., Wang, Y., Lu, F., Guan, M., & Wu, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1529231 · Cited by 16
Bila, J. S., Dotlić, J., Andjić, M., Ivanović, K., Micić, J., Tulić, L., Pupovac, M., Stojnić, J., Vuković, I., & Ivanovic, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165642 · Cited by 25
“Obesity is associated with restrained ovulation and high LH serum levels that affect thecal cells and increase functional ovarian hyperandrogenism by upregulating ovarian androgen synthesis [28,33,34].”
InfluentialLiu, S., Zhao, X., Meng, Q., & Li, B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293447 · Cited by 14
RetractedMukherjee, P., Sanyal, S., Chadha, S., & Mukherjee, S. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303266512231103075551 · Cited by 19
Hu, R., Huang, Y., Liu, Z., Dong, H., Ma, W., Song, K., Xu, X., Wu, X. W., Geng, Y., Li, F., et al. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104296 · Cited by 17
Shamsi, M., Ganji, A., Mosayebi, G., Amirhoseiny, E. S., Shohani, S., & Ghazavi, A. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03936-7 · Cited by 18
You, X., Yang, W., Li, X., Li, X., Huang, Y., & Huang, C. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02615-3 · Cited by 18
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Colca, J. R., Tanis, S. P., Kletzien, R. F., & Finck, B. N. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263369 · Cited by 15
“There has also been a long-term interest in the potential of insulin sensitizers to treat polycystic ovary syndrome (PCOS) [78].”
BackgroundGut microbiota and risk of polycystic ovary syndrome: Insights from Mendelian randomization
Li, J., Chen, Y., Zhang, Y., Zeng, L., Li, K.-W., Xie, B.-Z., Luo, S., & Gao, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22155 · Cited by 18
“Current understanding suggests that PCOS is a multifactorial disease involving various factors such as genetics, inflammation, gut microbiota, endocrine hormones, and insulin resistance [4,5].”
BackgroundArora, S., Vedpal, & Chauhan, N. (2024) · Multimedia Tools and Applications · doi:10.1007/s11042-024-19707-6 · Cited by 20
Wu, S., Wu, Y., Fang, L., & Lu, X. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-024-07131-5 · Cited by 17
“Consequently, IR, adipose tissue dysfunction, hyperandrogenemia, and LGCI may cooperate with each other in the vicious circle leading to the pathogenesis of PCOS [33].”
Role of Renin-Angiotensin-Aldosterone System and Cortisol in Endometriosis: A Preliminary Report
Sabbadin, C., Saccardi, C., Andrisani, A., Vitagliano, A., Marin, L., Ragazzi, E., Bordin, L., Ambrosini, G., & Armanini, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010310 · Cited by 14
“In particular, in PCOS, which is frequently associated with endometriosis, the use of SP has been proposed not only as an anti-androgen, but also as an anti-MR, to reduce the side effects related to the activation of the renin-angiotensinaldosterone system, represented by increased ARR [14,35,36].”
BackgroundSelf-citationZeng, H., Zhang, Y., Huang, S., Wu, J., Ren, W., Zhou, L., Huang, L., & Ye, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1223768 · Cited by 19
“The side-effects of spironolactone include hyperkalemia, transient polyuria, gastrointestinal discomfort, nausea, breast tenderness, allergic reactions, somnolence, headache, vertigo, and menstrual irregularity (35).”
BackgroundGudović, A., Bukumirić, Z., Milinčić, M., Pupovac, M., Andjić, M., Ivanović, K., & Spremović-Radjenović, S. (2024) · Biomedicines · doi:10.3390/biomedicines12020349 · Cited by 22
“The role of insulin resistance in the development of PCOS has been extensively studied, and it is widely accepted that IR is an independent factor apart from obesity that plays a significant role in the molecular mechanisms leading to increased androgen synthesis in the ovary [5].”
BackgroundAydın, H. L., Dayan, B. S., & GÜNGÖR, N. D. (2023) · Journal of Controversies in Obstetrics & Gynecology and Pediatrics · doi:10.51271/jcogp-0015 · Cited by 12
Magalhães, F. M. V., Pestana, R. M. C., Ferreira, C. N., Silva, I. D. F. O., Cândido, A. L., de Oliveira, F. R., dos Reis, F. M., & Gomes, K. B. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0416 · Cited by 15
“Notably, PCOS is also associated with low-grade chronic systemic inflammation (9).”
BackgroundWang, J., Huang, Z., Cao, Z., Luo, Y., Liu, Y., Cao, H., Tang, X., & Fang, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011146 · Cited by 12
“Insulin resistance is central to the pathogenesis of PCOS, where prolonged IR can lead to hyperinsulinemia, exacerbating PCOS symptoms [21,22] and resulting in anovulation and poor follicular development.”
BackgroundLi, J., Zheng, R., Shen, Y., Zhuo, Y., Lu, L., Song, J., Li, J., Lai, M., Zhu, H., Hu, M., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156294 · Cited by 13
Body mass index is a good predictor of metabolic abnormalities in polycystic ovary syndrome
Fruzzetti, F., Fidecicchi, T., Benelli, E., Baldari, F., & Tonacchera, M. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02210-4 · Cited by 15
“Hyperandrogenism in particular is known to be associated to metabolic complications, like IR and hyper-insulinemia [22].”
Colombo, G. E., Pirotta, S., & Sabag, A. (2023) · Seminars in Reproductive Medicine · doi:10.1055/s-0043-1777116 · Cited by 28
“6 Beyond pathogenesis related to excess adiposity, it is thought that insulin resistance is exacerbated through interactions with hyperandrogenism.”
BackgroundZhou, Y., Wang, X., Guo, S., Li, R., Li, Y., Yu, Y., & Liu, T. H. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2302402 · Cited by 14
“Recent studies have also shown that inflammation may be a potential risk factor for PCOS [22].”
Khobragade, N. H., Sheth, D. B., Patel, C. A., Beladiya, J., Patel, S. P., & Dalal, M. (2024) · Steroids · doi:10.1016/j.steroids.2024.109455 · Cited by 14
Panchpuri, M., Kisku, A., Painuli, R., Pant, G., & Kumar, C. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02117-5 · Cited by 13
“PCOS is associated with anovulatory infertility in 75% of affected women and is caused by androgen hormone excess that results in irregular or absent menstrual cycles (Armanini et al. 2022).”
Chan, J. L., Masini, I., & Pisarska, M. D. (2026) · Journal of Clinical Investigation · doi:10.1172/jci202824 · Cited by 22
“Production of androgens within theca cells is mainly stimulated by LH (40).”
Gu, R., Dai, F., Xiang, C., Chen, J., Yang, D., Tan, W., Wang, Z., Liu, H., & Cheng, Y. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106410 · Cited by 13
Roy, M., Parveen, R., Khan, P. M., Majid, H., Pathak, M., Saxena, R. K., & Agarwal, N. B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2407513 · Cited by 11
“There is an increased risk of developing type-2 diabetes mellitus, hypertension, cardiovascular disorders, dys-lipidaemia, and endometrial cancer in PCOS patients [2].”
Biochemical classification diagnosis of polycystic ovary syndrome based on serum steroid hormones
Wang, M., Zhang, S., He, J., Zhang, T., Zhu, H., Sun, R., & Yang, N. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106626 · Cited by 14
Pathophysiological insights into asprosin: an emerging adipokine in reproductive health
Khan, S., Syeda, S., Raghuvanshi, Y., & Shrivastava, A. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09975-4 · Cited by 15
Liang, R., Sheng, M., Li, X., Jin, J., & Yi, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116551 · Cited by 10
A Cross-Sectional Study of Alzheimer-Related Proteins in Women with Polycystic Ovary Syndrome
Butler, A. E., Moin, A. S. M., Sathyapalan, T., & Atkin, S. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021158 · Cited by 12
“…in the prevalence of metabolic features, including type 2 diabetes (T2D); hypertension; and, potentially, cardiovascular disease [1,2] and fatty liver disease [3], the mechanism of which is still unclear, though insulin resistance and obesity-related inflammation have been implicated [1,4].”
BackgroundDepression symptoms and quality of life in women with polycystic ovary syndrome
Koçak, D. Y., & Uğurlu, M. (2022) · Perspectives In Psychiatric Care · doi:10.1111/ppc.13131 · Cited by 15
Niepsuj, J., Piwowar, A., Franik, G., & Bizoń, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175316 · Cited by 14
“Polycystic ovary syndrome (PCOS) is a heterogeneous disease with difficulties in estimating etiological factors related to both its development and progression [1].”
BackgroundKumbhar, P., Chavan, R., Darekar, S., Kolekar, K. A., Sequeira, A., Vishwas, S., Gupta, G., Paudel, K. R., Singh, S. K., Dua, K., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03578-7 · Cited by 16
“An imbalance in the hypothal-amus-pituitary-ovarian axis signaling pathway can cause hyperandrogenism, resulting in the overproduction of LH, follicle-stimulating hormone (FSH; abnormal gonadotropin secretion) and insulin (Armanini et al. 2022).”
Wang, M., Huang, J., Shi, Y., Mprah, R., Ding, H., Zhang, S., & Li, C. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108089 · Cited by 10
Jin, Q., Xu, G. Z., Ying, Y., Liu, L., Zheng, H., Xu, S., Yin, P., & Chen, Y. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01595-5 · Cited by 14
“PCOS is associated with increased risks of infertility, type 2 diabetes mellitus (II-DM), and cardio-vascular disease (CVD) [4].”
Liu, D., Liu, D., & Zhou, K. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01617-2 · Cited by 11
Metadata
- Authors
- Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Armanini, Decio
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-08
- Volume
- 23
- Issue
- 8
- Pages
- 4110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9030414
- OpenAlex
- W4224247712
- Semantic Scholar
- 6ba01eafb58b7f3a48fb9c3789a3b5c603a63b92
- Cited by
- 324
- References
- 85
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 82 · 2023: 58 · 2022: 13
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, insulin resistance, inflammation, hyperandrogenism, PCOS pathogenesis, PCOS diagnosis, PCOS treatment, androgen receptor antagonists, metabolic disorders, oligoanovulation, PCOS phenotypes
- MeSH terms
- Female, Humans, Inflammation, Insulin Resistance, Metabolic Diseases, Polycystic Ovary Syndrome, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
